•
Sep 30, 2022

Prelude Therapeutics Q3 2022 Earnings Report

EPS
-$0.63
Previous year: -$0.66
-4.5%
Cash and Equivalents
$52M
Previous year: $61.4M
-15.3%
Free Cash Flow
-$21.4M
Previous year: -$22.4M
-4.8%
Total Assets
$242M
Previous year: $331M
-26.8%

Prelude Therapeutics

Prelude Therapeutics